三种序贯疗法治疗小儿肺炎支原体肺炎的效果

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of three sequential therapies consisting of Erythromycin,Azithromycin and Erythromycin combined with Azithromycin in the treatment of Mycoplasma pneumoniae pneumonia in children.Methods Retrospectively analyzed the clinical data of 150 children with Mycoplasma pneumoniae pneumonia admitted to the PLA 71st Army Group Hospital from October 2017 to July 2019.According to the medication plan,they were divided into the Erythromycin sequential therapy (HMS) group,the Azithromycin sequential therapy (AQMS) group and the Erythromycin-Azithromycin sequential therapy (HMS-AQMS) group,with 50 cases in each group.In HMS group,Erythromycin was given orally for 3 d after 7 d of intravenous drip.In AQMS group,Azithromycin was given intravenously for 5 d and stopped for 3 d,then orally for 5 d.In HMS-AQMS group,Erythromycin was given intravenously for 7 d and then Azithromycin was given orally for 3 d.The symptoms,signs,X-ray changes,clinical efficacy and adverse reactions of the three groups were compared..Results There were no significant differences in the time of fever abatement,cough disappearance,pulmonary rales disappearance and X-ray examination recovery time among the three groups (P>0.05).The total effective rate of HMS-AQMS group was 96.0%,which was higher than that of HMS group(86.0%) and AQMS group (88.0%),the difference was statistically significant (P<0.05).There was no significant difference in the total incidence of adverse reactions among the three groups (P>0.05).Conclusion Erythromycin-Azithromycin continuous therapy in the treatment of children with Mycoplasma pneumoniae pneumonia has better curative effect and lower adverse reactions,so it is worthy of promotion and application in clinical practice.

Key words： Erythromycin Azithromycin Sequential therapy Mycoplasma pneumoniae pneumonia Effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yan-li
	SHANG Ying
	WANG Zeng-hui
	HONG Qian

Cite this article:

LI Yan-li,SHANG Ying,WANG Zeng-hui, et al. Effect of three sequential therapy on children with Mycoplasma pneumoniae pneumonia[J]. 中国当代医药, 2020, 27(36): 106-108转112.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I36/106

[1]	Jain S，Williams DJ，Arnold SR，et al.Community-acquired pneumonia requiring hospitalization among U.S.children[J].N Engl J Med，2015，372（9）：835-845.
[2]	Sharma L，Losier A，Tolbert T，et al.Pneumonia Updates on Legionella，Chlamydophila，and Mycoplasma Pneumonia[J].Clin Chest Med，2017，38（1）：45.
[3]	马素素，陆丽羽，武书鸿.对儿童支原体肺炎临床治疗的分析[J].世界最新医药信息文摘，2018，18（98）：174-176.
[4]	周晨，易燕，许婷.阿奇霉素序贯治疗小儿肺炎支原体感染的精细化护理分析[J].中国医药科学，2020，10（18）：141-143.
[5]	崔爱莲.阿奇霉素与红霉素序贯疗法对患儿肺炎支原体肺炎的临床疗效及安全性比较[J].抗感染药学，2018，15（10）：1717-1719.
[6]	刘晓蓉，缪华.红霉素、阿奇霉素序贯疗法与单用阿奇霉素治疗小儿肺炎支原体肺炎的临床疗效评价[J].现代诊断与治疗，2017，28（11）：1994-1995.
[7]	高璐，洪倩，朱斌.阿奇霉素两种给药方案治疗小儿支原体肺炎的疗效及经济学评价[J].中国医院用药评价与分析，2018，18（4）：458-460.
[8]	陈士垣，夏雯.小儿肺炎支原体感染的肺外并发症[J].中国实用儿科杂志，1993，8（3）：200-203.
[9]	《抗菌药物临床试验技术指导原则》写作组.抗菌药物临床试验技术指导原则[J].药物评价与管理，2014，（9）：844-856.
[10]	宋春美.小儿肺炎支原体肺炎发病机制的研究进展[J].中国城乡企业卫生，2019，34（8）：61-63.
[11]	王秀琴.小儿肺炎支原体肺炎的临床特点及诊治分析[J].临床研究，2018，47（10）：1195-1196.
[12]	高建英.小儿肺炎支原体肺炎的治疗方法探讨[J].中西医结合心血管病电子杂志，2020，8（5）：60，77.
[13]	齐辉.红霉素联合阿奇霉素治疗小儿肺炎支原体肺炎的临床疗效分析[J].中国现代药物应用，2020，14（7）：130-132.
[14]	李娜，景淑军，崔振泽.红霉素与阿奇霉素治疗小儿肺炎支原体肺炎的效果观察及有效率影响分析[J].中国医药指南，2020，18（4）：143-144.
[15]	胡薇薇.红霉素联合阿奇霉素治疗小儿肺炎支原体肺炎的临床效果及药学分析[J].中国现代医生，2018，56（11）：98-99，103.
[16]	任德旭，王成.阿奇霉素与红霉素用于小儿肺炎支原体肺炎序贯治疗的临床效果及安全性比较[J].临床合理用药杂志，2019，12（29）：89-90.
[17]	李俊枝.研究红霉素联合阿奇霉素治疗小儿肺炎支原体肺炎的临床价值[J].世界最新医学信息文摘，2018，18（60）：142.
[18]	谭头娇.红霉素联合阿奇霉素序贯疗法治疗小儿支原体肺炎的效果观察[J].中国当代医药，2013，20（26）：80-81.